Accendra Health, Inc.

Accendra Health, Inc. ( ACH ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Will Parrish - VP of Strategy, Corporate Development, & IR Kenneth Gardner-Smith - President, CEO & Director Jonathan Leon - Executive VP, CFO & Corporate Treasurer Conference Call Participants Rishi Parekh - JPMorgan Chase & Co, Research Division Presentation Operator Good evening, and thank you for standing by. Welcome to Accendra Health's Third Quarter 2026 Earnings Conference Call.

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. “Over the several weeks since I started, a number of themes have become clear to me. We have strong brands, favorable end markets, and a teammate popula.

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged. “We are pleased to have worked with our banking partner to extend the Receivables Sale Program until.

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 27, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with Section 802.01B of the NYSE's continued listing standards that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders' equity of not less than $50.0 millio.